Preliminary experience using high-intensity focused ultrasound for the treatment of kidney and liver tumours
Illing RO. et al, (2004), BRITISH JOURNAL OF CANCER, 91, S21 - S21
Contrast-enhanced ultrasound assessment of tissue response to high-intensity focused ultrasound.
Kennedy JE. et al, (2004), Ultrasound Med Biol, 30, 851 - 854
DNA repair pathways in drug resistance in melanoma.
Bradbury PA. and Middleton MR., (2004), Anticancer Drugs, 15, 421 - 426
DNA repair pathways in drug resistance in melanoma
Bradbury PA. and Middleton MR., (2004), ANTI-CANCER DRUGS, 15, 421 - 426
High-intensity focused ultrasound for the treatment of liver tumours.
Kennedy JE. et al, (2004), Ultrasonics, 42, 931 - 935
Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma.
Danson S. et al, (2003), Cancer, 98, 542 - 553
Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma.
Danson S. et al, (2003), J Clin Oncol, 21, 2551 - 2557
Health-related quality of life in patients with advanced metastatic melanoma: results of a randomized phase III study comparing temozolomide with dacarbazine.
Kiebert GM. et al, (2003), Cancer Invest, 21, 821 - 829
Improvement of chemotherapy efficacy by inactivation of a DNA-repair pathway.
Middleton MR. and Margison GP., (2003), Lancet Oncol, 4, 37 - 44
Brain metastases in melanoma: a European perspective.
Cattell E. et al, (2002), Semin Oncol, 29, 513 - 517
Effect of O6-(4-bromothenyl)guanine on different temozolomide schedules in a human melanoma xenograft model.
Middleton MR. et al, (2002), Int J Cancer, 100, 615 - 617
Pharmacokinetics of histamine dihydrochloride in healthy volunteers and cancer patients: implications for combined immunotherapy with interleukin-2.
Middleton M. et al, (2002), J Clin Pharmacol, 42, 774 - 781
Assessing outcomes in palliative chemotherapy.
Cattell E. et al, (2002), Expert Opin Pharmacother, 3, 693 - 700
Toxicity of temozolomide with response modifiers in metastatic malignant melanoma
Lorigan P. et al, (2002), BRITISH JOURNAL OF CANCER, 86, S68 - S68
Effect of temozolomide on central nervous system relapse in patients with advanced melanoma.
Paul MJ. et al, (2002), Melanoma Res, 12, 175 - 178
Randomized phase II study of cyclophosphamide, doxorubicin, and vincristine compared with single-agent carboplatin in patients with poor prognosis small cell lung carcinoma.
White SC. et al, (2001), Cancer, 92, 601 - 608
Temozolomide: a novel oral alkylating agent.
Danson SJ. and Middleton MR., (2001), Expert Rev Anticancer Ther, 1, 13 - 19
Adjuvant interferon in melanoma - a resurrection?
Middleton MR. and Thatcher N., (2001), Br J Cancer, 84, 1141 - 1142